The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Review Article
Cisplatin-Induced Renal Salt Wasting Syndrome
Abstract
Cisplatin was the first platinum compound to be introduced as a chemotherapeutic agent with antineoplastic activity against a wide variety of solid tumors. Renal impairment with a decline in glomerular filtration has been the classical nephrotoxicity of cisplatin. Renal salt wasting syndrome is yet another, though it is not common. Previous studies were identified by searching the Pubmed database using the following keywords: cisplatin, cisplatin nephrotoxicity, renal salt wasting, and salt loosing nephropathy. Renal salt wasting syndrome has been described in 17 case reports since 1984. It is a rare side effect of cisplatin that manifests with polyuria, hypovolemia, and hyponatremia, and, because of similarities in clinical settings and laboratory values, it is frequently misdiagnosed as a syndrome of inappropriate antidiuretic hormone. Other causes of polyuria and hyponatremia should be excluded. Treatment aims at restoring the lost water and salt. Substituting cisplatin with carboplatin depends on individual clinical settings. Prognosis is excellent, as recovery was the rule in all the reported cases.
Key Points
* Cisplatin can induce a rare form of nephrotoxicity characterized by water and salt wasting.
* This syndrome shares many similarities with syndrome of inappropriate antidiuretic hormone.
* The treatment aims at restoring the intravascular volume through salt and water administration.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977;39:1357–1361.
2. Wittes RE, Brescia F, Young CW, et al. Combination chemotherapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 1975;32:202–207.
3. DeConti RC, Toftness BR, Lange RC, et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973;33:1310–1315.
4. Kuhlmann MK, Burkhardt G, Köhler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997;12:2478–2480.
5. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460–464.
6. Kröning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol2000;45:43–49.
7. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. [Review]. Oncol Rep 2003;10:1663–1682.
8. Daley-Yates PT, McBrien DC. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem Pharmacol 1985;34:2363–2369.
9. Ekborn A, Lindberg A, Laurell G, et al. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 2003;51:36–42.
10. Townsend DM, Deng M, Zhang L, et al. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1–10.
11. Gemba M, Nakatani E, Teramoto M, et al. Effect of cisplatin on calcium uptake by rat kidney cortical mitochondria. Toxicol Lett 1987;38:291–297.
12. Gordon JA, Gattone VH II. Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 1986;250:F991–F998.
13. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835–842.
14. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 2004;65:490–499.
15. Nechay BR, Neldon SL. Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid. Cancer Treat Rep 1984;68:1135–1141.
16. Uozumi J, Litterst CL. The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother Pharmacol 1985;15:93–96.
17. Arany I, Megyesi JK, Kaneto H, et al. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 2004;287:F543–F549.
18. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 1993;50:147–158.
19. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 1989;25:1–9.
20. Miura K, Goldstein RS, Pasino DA, et al. Cisplatin nephrotoxicity: role of filtration and tubular transport of cisplatin in isolated perfused kidneys. Toxicology 1987;44:147–158.
21. Kaushal GP, Kaushal V, Hong X, et al. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 2001;60:1726–1736.
22. Yamate J, Sato K, Ide M, et al. Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet Pathol 2002;39:322–333.
23. Guinee DG Jr, van Zee B, Houghton DC. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer 1993;71:4050–4054.
24. Thurau K, Boylan JW. Acute renal success. The unexpected logic of oliguria in acute renal failure. Am J Med 1976;61:308–315.
25. Daugaard G. Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 1990;37:1–12.
26. Daugaard G, Abildgaard U, Holstein-Rathlou NH, et al. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 1988;44:164–172.
27. Isnard-Bagnis CD. Anticancer drugs, in De Broe ME, Porter GA, Bennett WM, Verpooten GA (eds): Clinical Nephrotoxins. Norwell, MA, Kluwer Academic, 2003, ed 2, pp 353–372.
28. Meyer KB, Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab 1994;20:201–213.
29. Kim SW, Lee JU, Nah MY, et al. Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol 2001;12:875–882.
30. Vassal G, Rubie H, Kalifa C, et al. Hyponatremia and renal sodium wasting in patients receiving cisplatinum. Pediatr Hematol Oncol 1987;4:337–344.
31. Hutchison FN, Perez EA, Gandara DR, et al. Renal salt wasting in patients treated with cisplatin. Ann Intern Med 1988;108:21–25.
32. Rivkees SA. Differentiating appropriate antidiuretic hormone secretion, inappropriate antidiuretic hormone secretion and cerebral salt wasting: the common, uncommon, and misnamed. Curr Opin Pediatr 2008;20:448–452.
33 Kurtzberg J, Dennis VW, Kinney TR. Cisplatinum-induced renal salt wasting. Med Pediatr Oncol 1984;12:150–154.
34. Lammers PJ, White L, Ettinger LJ. Cis-platinum-induced renal sodium wasting. Med Pediatr Oncol 1984;12:343–346.
35. Peyrade F, Taillan B, Lebrun C, et al. Hyponatremia during treatment with cisplatin. Presse Med 1997;26:1523–1525.
36.Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. Am J Clin Oncol 2002;25:344–346.
37. Iyer AV, Krasnow SH, Dufour DR, et al. Sodium-wasting nephropathy caused by cisplatin in a patient with small-cell lung cancer. Clin Lung Cancer 2003;5:187–189.
38. Abdelghani L, Modha K, Albaddawi E, et al. Sodium-wasting nephropathy caused by cisplatin in esophageal cancer. J Support Oncol 2008;6:305–306.
39. Ivy HK. Renal sodium loss and bronchogenic carcinoma. Associated autonomic neuropathy. Arch Intern Med 1961;108:47–55.
40. Park D, Johnson R, Crean GP, et al. Orthostatic hypotension in bronchial carcinoma. Br Med J 1972;3:510–511.
41. Kusuki M, Iguchi H, Nakamura A, et al. The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer. Acta Otolaryngol Suppl 2004;554:74–77.
42. Littlewood TJ, Smith AP. Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin. Thorax 1984;39:636–637.
43. Otsuka F, Hayashi Y, Ogura T, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin. Intern Med 1996;35:290–294.
44. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. [Review]. Am J Med 2006;11(7 suppl 1):S36–S42.
45. Robertson GL. The use of vasopressin assays in physiology and pathophysiology. Semin Nephrol 1994;14:368–383.
46. Uribarri J, Oh MS, Carroll HJ. Salt-losing nephropathy. Clinical presentation and mechanisms. Am J Nephrol 1983;3:193–198.
47. Kojima J, Katayama Y, Moro N, et al. Cerebral salt wasting in subarachnoid hemorrhage rats: model, mechanism, and tool. Life Sci 2005;76:2361–2370.
48. Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med 1978;65:307–314.
49. Tscherning C, Rubie H, Chancholle A, et al. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994;73:1761–1763.
50. Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 1997;15:1844–1852.
51. Kelsen D, Atiq OT. Therapy of upper gastrointestinal tract cancers. Curr Probl Cancer 1991;15:235–294.
52. Wolf M, Havemann K, Drings P, et al. Alternating chemotherapy with doxorubicin, ifosfamide, and vincristine plus cisplatin and etoposide versus doxorubicin, ifosfamide, and vincristine plus carboplatinand etoposide in small cell lung cancer, in Bunn PA, Canetta R, Ozols RF, et al (eds):Carboplatin (JM-8): Current Perspectives and Future Directions. Philadelphia, PA, WB Saunders, 1990, pp 283–294.
53. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601–607.
54. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–3200.
55. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78:1479–1487.
56. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847–857.
